Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer: analysis of a retrospective cohort and a structured literature review
Background: Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. Patients and Methods: We retrospectively reviewed p...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2017
|
| In: |
Urologia internationalis
Year: 2017, Volume: 99, Issue: 4, Pages: 414-421 |
| ISSN: | 1423-0399 |
| DOI: | 10.1159/000477943 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1159/000477943 Verlag, Volltext: https://www.karger.com/Article/FullText/477943 
|
| Author Notes: | Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Arne Strauss, Thomas Stefan Worst, Philipp Nuhn, Christian Bolenz, Elmar Heinrich |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157427614X | ||
| 003 | DE-627 | ||
| 005 | 20220814134536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180508s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000477943 |2 doi | |
| 035 | |a (DE-627)157427614X | ||
| 035 | |a (DE-576)50427614X | ||
| 035 | |a (DE-599)BSZ50427614X | ||
| 035 | |a (OCoLC)1341009301 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hardenberg, Jost von |d 1982- |e VerfasserIn |0 (DE-588)1020494328 |0 (DE-627)688149278 |0 (DE-576)360578241 |4 aut | |
| 245 | 1 | 0 | |a Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer |b analysis of a retrospective cohort and a structured literature review |c Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Arne Strauss, Thomas Stefan Worst, Philipp Nuhn, Christian Bolenz, Elmar Heinrich |
| 264 | 1 | |c December 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.05.2018 | ||
| 520 | |a Background: Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. Patients and Methods: We retrospectively reviewed patients treated with fourth-line or beyond CAB for mCRPC after failure of previous therapies with docetaxel, abiraterone acetate, enzalutamide and/or radium-223. The progression-free survival (PFS) and the overall survival (OS) were estimated using the Kaplan-Meier method and compared to published data based on a structured literature review. The hospitalization rate was recorded. Factors influencing 6-months OS were analyzed. Results: Fifteen patients were identified at 4 institutions and included in the analysis. The median PFS was 104 days (range 47-397 days). The median time to death was 10 months (range 2-16). PFS and OS data are in accordance with 17 published patients so far. During the therapy, eleven (73%) of the patients were hospitalized. Prostate-specific antigen (PSA, 500 units; hazards ratio [HR] 1.491, 95% CI 1.000-2.0175), white blood cell count (HR 0.425, 95% CI 0.108-0.952), hemoglobin (HR 0.6014, 95% CI 0.2942-1.0758), and alkaline phosphatase (100 units; HR 1.0964, 95% CI 1.000-1.2859) correlate with 6-months OS. Conclusions: CAB beyond the third-line is often accompanied by hospitalization. PFS is a significant proportion of the median time of OS. The baseline laboratory might be a good indicator for the decision between CAB and best-supportive care. | ||
| 700 | 1 | |a Schwartz, Maike |d 1990- |e VerfasserIn |0 (DE-588)115864051X |0 (DE-627)1020632003 |0 (DE-576)504275356 |4 aut | |
| 700 | 1 | |a Worst, Thomas |d 1985- |e VerfasserIn |0 (DE-588)1028335679 |0 (DE-627)73058500X |0 (DE-576)375827501 |4 aut | |
| 700 | 1 | |a Nuhn, Philipp |d 1981- |e VerfasserIn |0 (DE-588)136112951 |0 (DE-627)694090808 |0 (DE-576)30083909X |4 aut | |
| 700 | 1 | |a Heinrich, Elmar |d 1976- |e VerfasserIn |0 (DE-588)1019458364 |0 (DE-627)690906943 |0 (DE-576)356127583 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologia internationalis |d Basel : Karger, 1955 |g 99(2017), 4, Seite 414-421 |h Online-Ressource |w (DE-627)265510333 |w (DE-600)1464417-4 |w (DE-576)276270991 |x 1423-0399 |7 nnas |a Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer analysis of a retrospective cohort and a structured literature review |
| 773 | 1 | 8 | |g volume:99 |g year:2017 |g number:4 |g pages:414-421 |g extent:8 |a Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer analysis of a retrospective cohort and a structured literature review |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000477943 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/477943 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180508 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1019458364 |a Heinrich, Elmar |m 1019458364:Heinrich, Elmar |d 60000 |d 63100 |e 60000PH1019458364 |e 63100PH1019458364 |k 0/60000/ |k 1/60000/63100/ |p 9 |y j | ||
| 998 | |g 136112951 |a Nuhn, Philipp |m 136112951:Nuhn, Philipp |d 60000 |d 63100 |e 60000PN136112951 |e 63100PN136112951 |k 0/60000/ |k 1/60000/63100/ |p 7 | ||
| 998 | |g 1028335679 |a Worst, Thomas |m 1028335679:Worst, Thomas |d 60000 |d 63100 |e 60000PW1028335679 |e 63100PW1028335679 |k 0/60000/ |k 1/60000/63100/ |p 6 | ||
| 998 | |g 115864051X |a Schwartz, Maike |m 115864051X:Schwartz, Maike |d 60000 |d 63100 |e 60000PS115864051X |e 63100PS115864051X |k 0/60000/ |k 1/60000/63100/ |p 2 | ||
| 998 | |g 1020494328 |a Hardenberg, Jost von |m 1020494328:Hardenberg, Jost von |d 60000 |d 63100 |e 60000PH1020494328 |e 63100PH1020494328 |k 0/60000/ |k 1/60000/63100/ |p 1 |x j | ||
| 999 | |a KXP-PPN157427614X |e 3008541089 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"issn":["1423-0399"],"eki":["265510333"],"zdb":["1464417-4"]},"disp":"Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer analysis of a retrospective cohort and a structured literature reviewUrologia internationalis","part":{"text":"99(2017), 4, Seite 414-421","volume":"99","year":"2017","pages":"414-421","extent":"8","issue":"4"},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 13.04.2021"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1955","dateIssuedDisp":"1955-","publisher":"Karger","publisherPlace":"Basel"}],"recId":"265510333","language":["ger"],"title":[{"title_sort":"Urologia internationalis","title":"Urologia internationalis","subtitle":"an independent international forum for clinically oriented research"}],"pubHistory":["1.1955 -"]}],"person":[{"display":"Hardenberg, Jost von","given":"Jost von","family":"Hardenberg","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Schwartz, Maike","role":"aut","roleDisplay":"VerfasserIn","given":"Maike","family":"Schwartz"},{"given":"Thomas","family":"Worst","roleDisplay":"VerfasserIn","role":"aut","display":"Worst, Thomas"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Philipp","family":"Nuhn","display":"Nuhn, Philipp"},{"given":"Elmar","family":"Heinrich","roleDisplay":"VerfasserIn","role":"aut","display":"Heinrich, Elmar"}],"id":{"eki":["157427614X"],"doi":["10.1159/000477943"]},"note":["Gesehen am 08.05.2018"],"origin":[{"dateIssuedDisp":"December 2017","dateIssuedKey":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"157427614X","title":[{"subtitle":"analysis of a retrospective cohort and a structured literature review","title":"Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer","title_sort":"Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer"}],"name":{"displayForm":["Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Arne Strauss, Thomas Stefan Worst, Philipp Nuhn, Christian Bolenz, Elmar Heinrich"]},"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a HARDENBERGONCOLOGICR2017 | ||